Trials / Completed
CompletedNCT04028349
ZEBOVAC (Ebola Vaccine Trial, Ad26.ZEBOV/MVA-BN-Filo)
An Open-label, Single Arm Study to Provide Additional Information on Immunogenicity and Safety of Ad26.ZEBOV/MVA-BN-Filo
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 800 (actual)
- Sponsor
- MRC/UVRI and LSHTM Uganda Research Unit · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
An open-label, single arm phase II study of the candidate Ebola Vaccine Ad26.ZEBOV/MVA-BN®-Filo
Detailed description
This is an interventional, single arm, open-label, non-randomized, phase II study to accumulate additional data on immunogenicity and safety of Ad26.ZEBOV/MVA-BN®-Filo against Ebola virus disease. It also has a qualitative component to better understand knowledge about Ebola virus disease and the perception and attitudes towards the vaccine amongst participants (Healthcare and Frontline workers).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ad26.ZEBOV/MVA-BN-Filo | Candidate Ebola Vaccine |
Timeline
- Start date
- 2019-08-01
- Primary completion
- 2021-03-19
- Completion
- 2021-03-19
- First posted
- 2019-07-22
- Last updated
- 2021-05-12
Locations
1 site across 1 country: Uganda
Source: ClinicalTrials.gov record NCT04028349. Inclusion in this directory is not an endorsement.